Global Alzheimer’s Platform Foundation® (GAP) Condemns CMS Preliminary Coverage Decision on First Disease Modifying Drug for Alzheimer’s as Repudiation of President’s Promise to Advance Treatments for Alzheimer’s for all Americans
GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for […]